Zoetis (ZTS) Stock Price Drops After Q3 Results Squeeze Margins

Zoetis just reported Q3 2026 numbers that were steady rather than spectacular, yet the stock still took a hit. Shares closed down about 3% to US$79.43, giving you a classic case of sentiment running hotter than the actual print. Revenue landed at US$2.39b and adjusted net income came in at US$720m, essentially in line with what management had been steering investors toward.

The real story sits in margins and mood. Net margin on a trailing basis remains high at 26.4%, even as it has slipped from last year. Today’s price drop looks more like a collective shrug that turned into a sell button than a clear verdict that Zoetis’ earnings power has suddenly cracked.

Love Zoetis’ high margins but worried about sentiment swinging harder than the actual earnings results? Check out our list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$2,391m vs. US$2,422m (down 1.3%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$591m vs. US$721m (down 18.0%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$1.44 vs. US$1.63 (down 11.8%)
• Trailing Net Margin (Last 12 Months vs. Prior Year): 26.4% vs. 27.9% (compression of 1.5 percentage points)

Dermatology is dragging results while Zoetis readies long-acting Cytopoint. Ask Charlie what Zoetis expects from long-acting Cytopoint in 2027.

Zoetis Bull Case: Early Signs Of Execution, Not Escape Velocity

The bullish story hinges on Zoetis converting its broad product engine into higher quality growth rather than just defending share.

"Bullish analysts expect Zoetis to use its long-acting OA pain launches, renal and oncology pipeline, and expanding diagnostics ecosystem to reignite growth across companion animal and livestock portfolios over time."

Recent numbers show pieces of that thesis starting to appear, but not yet changing the whole picture. Companion diagnostics revenue grew 13%, and livestock climbed 7%, which supports the diversification angle. OA pain revenue is up only 2% overall, with U.S. actually down. International uptake is helping but not yet offsetting pressure in core companion categories.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Zoetis Bear Case: Pipeline Progress, Core Weak Spots

Bearish investors argue Zoetis is not yet proving that its pipeline can carry the load as core pet drugs tire.

"The main thing that has to go right is that Zoetis converts its broad pipeline in areas like renal disease, oncology, cardiology, anxiety, obesity, osteoarthritis, and diagnostics into products that offset companion animal softness and heavier use of rebates and promotions."

Q3 shows that concern is not theoretical. Global companion animal revenue fell 5% and U.S. pet sales declined 8%, while dermatology dropped 16% and U.S. OA pain slipped 12%. Diagnostics and livestock grew 13% and 7%, but were not large enough to replace pressure in flagship pet therapies, so the bar for future launches remains high.

Hunt Mispriced Stories Before They Move

Zoetis just reminded you that solid businesses can still see sharp mood swings around a single quarter. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 27% below our estimate - uses recent acquisitions, lower cost deposits and efficiency upgrades to reshape its banking platform and address credit risk.
• Company 2 - 31% below our estimate - builds a bank funded digital lending engine relying on automation, tax assets and a low cost deposit base for installment loan products.
• Company 3 - 45% below our estimate - advances late stage therapies in kidney disease, gene editing, acute pain and endocrinology to extend its franchise beyond a single respiratory condition.

Those are three of them. See the full list of 41 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com